Pressure BioSciences, Inc. (PBIO)
Pressure BioSciences, Inc. (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary application development and sales efforts are in the biomarker discovery and forensics areas. Customers also use our products in other areas, such as drug discovery & design, bio-therapeutics characterization, soil & plant biology, vaccine development, histology, and counter-bioterror applications.
Description
Pressure BioSciences, Inc. (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary application development and sales efforts are in the biomarker discovery and forensics areas. Customers also use our products in other areas, such as drug discovery & design, bio-therapeutics characterization, soil & plant biology, vaccine development, histology, and counter-bioterror applications.
Contact Information
14 Norfolk Avenue
South Easton, MA 02375
Website: http://www.pressurebiosciences.com
Phone: (508) 230-1828
Email: info@pressurebiosciences.com
Financial Reporting/Disclosure
Reporting Status : U.S. Reporting: SEC Reporting
Audited Financials : Audited
Latest Report : Sep 30, 2016 10-Q
Regulatory Agency : Financial Industry Regulatory Authority
CIK : 0000830656
Fiscal Year End : 12/31
OTC Marketplace : OTCQB
Profile Data
SIC – Industry Classification : 3826 – Analytical instruments
Incorporated In: : MA, USA
Year of Inc. : 2004
Employees : 9 a/o Nov 09, 2014
Company Officers/Contacts
Richard T. Schumacher ┃ CEO, President, Acting CFO
Edmund Ting ┃ Senior VP, Engineering
Alexander Lazarev ┃ VP, R&D
Nathan P. Lawrence ┃ VP, Sales & Mktg.
Company Directors
Jeffrey N. Peterson ┃ Chairman
Vito J. Mangiardi
Kevin A. Pollack
Michael S. Urdea
Service Providers
Accounting/Auditing Firm
MaloneBailey, LLP
9801 Westheimer Road
Suite 1100
Houston,TX,77042
United States
Securities Counsel
Lucosky Brookman LLP OTCQX Sponsor
101 Wood Avenue South
5th Floor
Woodbridge,NJ,08830
United States
Investor Relations Firm
Not Available
Company History
- Formerly=Boston Biomedica, Inc. until 9-04